Bristol-Myers Squibb Company (BMY)
- Motley Fool
What's the Outlook for Illumina?
Genomic sequencing leader Illumina (NASDAQ: ILMN) recently provided guidance for 2022 and revealed some of its plans for the year. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss the outlook for Illumina going forward. Keith Speights: Hey, there's a company that you and I haven't talked about very much, at least, I'm going to say at least over the last seven or eight months and maybe longer than that.
- Motley Fool
What's Behind Bristol Myers Squibb's Latest Partnership?
Bristol Myers Squibb (NYSE: BMY) has made some big acquisitions in the past, and it's now hinting that more deals could be on the way. The pharmaceutical giant recently announced a smaller licensing agreement with Century Therapeutics (NASDAQ: IPSC) instead of a big acquisition. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss what's behind Bristol Myers Squibb's latest partnership.
- Zacks
Bristol Myers Squibb (BMY) Stock Moves -1.61%: What You Should Know
Bristol Myers Squibb (BMY) closed the most recent trading day at $63.54, moving -1.61% from the previous trading session.
